Search

You searched for "catheterisation"

283 results found

MRI screening for prostate cancer: a step towards a ‘prostagram’

7 January 2020 | | URO - Urologic Oncology, URO - Technology
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

Feeling like a fraud — imposter syndrome: what it is and what to do about it

17 April 2024 | | URO - Core Urology
Have you ever been plagued by feelings of incompetence despite evidence to the contrary, then this article is for you. Dr Dunay Schmulian provides insight into imposter syndrome and what to do about it. Excerpt 1 Consultant:That was excellent, and...

Molecular biology – bladder cancer

1 January 2014 | | URO - Basic Science Research, URO - Urologic Oncology
Background Bladder cancer is the most common cancer of the urinary tract and approximately 90% of bladder cancers diagnosed in North America and Europe are transitional cell carcinomas (TCC). For the purposes of diagnosis and treatment, bladder cancer is often...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

7 January 2021 | | URO - Urologic Oncology
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

The urologist’s tale

8 November 2021 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). The Canterbury Tales, written by Geoffrey Chaucer (c.1340’s-1400) in the 14th Century, is...

Burnout in surgery

5 May 2021 | | URO - Core Urology
When I was pregnant with my first child, I went to a talk on how to achieve work-life balance and avoid burnout. It was given by a highly respected Australian surgeon and I was eager to hear the secrets that...

Dogs and humans share a bladder cancer biomarker: a new discovery that opens doors for early detection and treatment

9 September 2025
A new scientific study has identified a new molecular biomarker that could help doctors detect aggressive early-stage bladder cancer, such as high-grade non-muscle invasive bladder cancer (NMIBC), in both dogs and humans. This discovery advances our knowledge of how aggressive...

The conservative assessment and treatment of mixed urinary and anal incontinence in women: a multidisciplinary approach

1 September 2019 | | URO - Functional / Reconstructive Urology, URO - Neurourology
Mixed urinary incontinence Urinary incontinence (UI) is considered to be a highly prevalent condition; however, depending upon the definitions used, actual reported prevalence rates can vary significantly. The International Consultation on Incontinence (ICI) review [1], reported unadjusted prevalence estimates for...

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

1 March 2017 | | URO - Uroradiology, URO - Urologic Oncology
Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

Focal therapy for prostate cancer – ready for prime time?

1 November 2016 | | URO - Basic Science Research, URO - Urologic Oncology
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

How do we tackle social injustice in urological cancer?

2 December 2024 | | URO - Urologic Oncology
Socioeconomic status as an established determinant of health and associated injustices is well recognised. Confronting these injustices and creating a fairer healthcare system is an ongoing challenge for many governments. In Scotland, the devolved government has created the Scottish Index...